Related Experiment Video

Updated: Aug 23, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer

Maria L Amador1, Manuel Hidalgo

  • 1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Clinical Colorectal Cancer
|June 23, 2004
PubMed

Insights

Targeting the epidermal growth factor receptor (EGFR) offers new hope for colorectal cancer patients. Research reviews EGFR-targeted therapies, including antibodies and small molecules, for improved treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Colorectal carcinoma is a leading global cancer with limited survival benefits from current treatments.
  • Epidermal growth factor receptor (EGFR) dysregulation is common in colorectal cancer, correlating with poor prognosis.
  • Novel therapeutic strategies targeting EGFR are essential for advanced colorectal cancer.

Purpose of the Study:

  • To comprehensively review preclinical and clinical data on EGFR-targeted therapies for colorectal cancer.
  • To explore the potential of inhibiting EGFR and its downstream pathways.
  • To discuss the integration of these novel agents into existing treatment paradigms.

Main Methods:

  • Review of current preclinical and clinical studies on EGFR-targeted drugs.
  • Analysis of therapeutic strategies including monoclonal antibodies and small-molecule inhibitors.
  • Evaluation of antitumor efficacy and patient response data.

Main Results:

  • EGFR-targeted therapies, including antibodies and kinase inhibitors, show preliminary antitumor activity in colorectal cancer.
  • Several EGFR-targeting agents are under investigation in ongoing clinical trials.
  • The efficacy of these therapies is influenced by specific biological contexts.

Conclusions:

  • Targeting the epidermal growth factor receptor (EGFR) represents a promising therapeutic avenue for colorectal cancer.
  • Further research is needed to define optimal patient populations and integrate EGFR inhibitors into treatment protocols.
  • Future directions include personalized medicine approaches for colorectal cancer based on EGFR status.

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...